文献速递类风湿关节炎

皮下与静脉超低剂量利妥昔单抗治疗类风湿关节炎的随机对照PK-PD非劣效试验

Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

结果显示AUC几何均值比0.99(90%CI 0.82-1.20),DAS28-CRP变化非劣效,但AUC估计不确定性使非劣效结论不能确定。

要点

  • 皮下与静脉超低剂量利妥昔单抗的AUC0-6m几何均值比为0.99(90%CI 0.82-1.20)。
  • 皮下组DAS28-CRP平均变化-0.39(95%CI -0.77至-0.004),非劣效于静脉组。
  • AUC估计随机误差中等,非劣效结论不能确定,皮下可作为替代选择。

核心结论

  • 皮下超低剂量利妥昔单抗的药代动力学非劣效于静脉给药,但因AUC估计不确定性不能确定结论。
  • 基于PK和PD参数,皮下超低剂量利妥昔单抗可作为静脉超低剂量利妥昔单抗的替代方案。

主要发现

  • AUC0-6m几何均值比为0.99(90%CI 0.82-1.20)。
  • AUC估计平均预测误差:静脉13.1(1.86%),皮下-3.40(-0.47%)。
  • AUC估计均方根误差:静脉140(19.8%),皮下142(19.5%)。
  • 皮下组DAS28-CRP平均变化-0.39(95%CI -0.77至-0.004),非劣效界值0.6。

关键数值与推荐

  • 主要终点AUC0-6m非劣效界值为0.8。
  • DAS28-CRP变化非劣效界值为0.6。

临床怎么用

  • 对于稳定低疾病活动且使用超低剂量利妥昔单抗的RA患者,皮下给药可能作为静脉给药的替代选择。

局限性

  • AUC估计存在中等随机误差,导致非劣效结论不能确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Ultra-low-dose rituximab is an effective treatment in RA. S.c. administration may further facilitate rituximab treatment, reduce infection risk and reduce costs. This study aimed to assess non-inferiority of s.c. vs i.v. rituximab regarding pharmacokinetic and pharmacodynamic outcomes. METHODS: In this randomized, open-label, non-inferiority study, RA patients with stable low disease activity on ultra-low-dose rituximab (500 mg or 200 mg every 6 months) were 1:1 randomized to receive rituximab 336 mg s.c. or 200 mg i.v., stratified by previous rituximab dose. Primary outcome was non-inferiority of s.c. to i.v. rituximab, based on the estimated rituximab serum concentration area under the curve during the first 6 months (AUC0-6m), with a non-inferiority margin of 0.8. AUCs were estimated using PK modelling. Secondary outcomes included change in DAS28-CRP compared with a non-inferiority margin of 0.6. RESULTS: Thirty-five patients were randomized (17 i.v., 18 s.c.). The geometric mean ratio for AUC0-6m was 0.99 (90% CI 0.82-1.20), with minimal bias [mean predication error: i.v. 13.1 (1.86%); s.c. -3.40 (-0.47%)] but moderate random prediction error [root mean square error: i.v. 140 (19.8%); s.c. 142 (19.5%)] for the AUC estimates. Mean change in DAS28-CRP was non-inferior for s.c. rituximab (-0.39, 95% CI -0.77 to -0.004). CONCLUSION: Our data suggest non-inferior pharmacokinetics for s.c. rituximab; however, this cannot be definitively concluded due to uncertainty of the AUC estimates. Nevertheless, based on pharmacokinetic and pharmacodynamic parameters, ultra-low-dose s.c. rituximab could be an alternative for ultra-low-dose i.v. rituximab.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bovens PMET, van der Togt CJT, den Broeder N, et al. Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial. Rheumatology (Oxford). 2026. PMID: 42610717. doi:10.1093/rheumatology/keag420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。